Vivet Therapeutics to Present Key Findings on its Gene Therapy Program forCerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
Gene therapy program VTX-806 demonstrated normalization of toxic bile acid metabolites in blood, liver, tendons and brain in a CTX mouse model for the first time, holding promise for curative treatment Long term characterization of B6.129-Cyp27a1tmlEl t/J CTX mouse model showed measurable motor alterations similar to those described in CTX patients validating model for translation […]
